Company Press Releases

Company Press ReleasesNick Bergh2020-09-28T18:23:21+00:00

TueMar 23rd, 2021

Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021

Lantern Pharma to Present New Data Supporting the Advancement [...]

WedMar 17th, 2021

Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

Lantern Pharma Announces Filing of Seven Patent Applications Globally [...]

WedMar 10th, 2021

Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial [...]

ThuJan 14th, 2021

Lantern Pharma Announces Pricing of $60 Million Public Offering

Lantern Pharma Announces Pricing of $60 Million Public Offering [...]

MonJan 4th, 2021

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program through Agreement with Califia Pharma

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) [...]

TueDec 15th, 2020

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Nick Bergh2020-12-15T16:52:47+00:00Tags: oncology research|

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood [...]

Let’s start a conversation about the future of cancer drug development.

We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.

Lantern Pharma, Inc. informs you that our website uses its own and third party cookies to improve our services and collect statistical information about your browsing. By clicking accept, we consider that you accept its use. For more information, or to know how to change the configuration, consult our Privacy Policy. I Accept